Jemperli, the first immuno-oncology option introduced to the field of endometrial cancer, can now be prescribed in general hospitals in Korea.

According to industry sources, GSK Korea’s PD-1 inhibitor Jemperli (dostarlimab) has passed the drug committee (DC) reviews of tertiary hospitals in Korea. Including the Seoul National University Hospital and Seoul Asan Medical Center.

The company has been gradually expanding its prescribing area after receiving reimbursement for Jemperli in December last year. While the number of hospitals that granted use of the drug is still small, GSK has been working to create an enabling environment for Jemperli prescriptions even before the reimbursement p